Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

September 07, 2017 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Announces CREATE-1 Interim Analysis Expected Year-End 2017

NEW YORK, Sept. 07, 2017 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
May 03, 2016 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Receives FDA Fast Track Designation for AXS-02 for the Treatment of the Pain of Knee Osteoarthritis Associated with Bone Marrow Lesions

NEW YORK, May 03, 2016 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ:AXSM), a clinical-stage biopharmaceutical company developing novel therapies for the management of central nervous...
March 28, 2016 07:00 ET | Source: Axsome Therapeutics, Inc.

Axsome Therapeutics Initiates Phase 3 Study of AXS-02 for Knee Osteoarthritis Associated with Bone Marrow Lesions

First Patient Enrolled in the COAST-1 StudyNon-Opioid, Oral, Targeted, Potentially First-in-Class Mechanism for PainNovel Biomarker-Based Approach for the Treatment of Knee Osteoarthritis...